GSK’s Nucala secures NICE COPD endorsement
In another landmark for GSK’s blockbuster respiratory drug, Nucala (mepolizumab), the UK’s health watchdog has recommended the therapy’s use by…
29 May 2026
Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medications. The…
29 May 2026
FDA grants priority review for Sanofi’s venglustat NDA
Sanofi has received a priority review from the US Food and Drug Administration (FDA) for its new drug application (NDA) for venglustat, an oral glucosylceramide synthase inhibitor (GCSi) intended for…
28 May 2026
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo
As core operations at the US Food and Drug Administration (FDA) remain stable despite ongoing shifts in senior leadership, the agency has made some notable decisions in the realm of…
27 May 2026
California startup Protuoso raises $9.5m for “mix-and-match” drug platform
Protuoso Biosciences has secured $9.5m in seed financing to develop its platform which combines multiple therapeutic modalities to target diseases through several pathways simultaneously. Founded by Willie Xiang and Tim…
27 May 2026
Kardigan targets IPO to support cardiology pipeline progression
Just under a year and a half after its debut, Kardigan is eyeing a listing on the Nasdaq to support the continued development of its in-licensed cardiology pipeline – adding…
27 May 2026
Autobahn’s elunetirom receives FDA fast track designation to treat adjunctive bipolar
Autobahn Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for elunetirom, its lead central nervous system (CNS)-directed thyroid hormone receptor agonist. Elunetirom is an…